ClinicalTrials.gg
CompletedNCT02019420Updated Jun 27, 2019Results posted

Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)

A Phase 3 interventional study of Tedizolid phosphate and Linezolid in Pneumonia, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-27.

Sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
726
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a 1:1 ratio, randomized, double-blind, double-dummy, multicenter, global Phase 3 study of tedizolid phosphate (TR-701 FA) 200 mg intravenous (IV) once daily for 7 days versus linezolid (Zyvox®, Zyvoxid®, etc) 600 mg IV every 12 hours for 10 days for the treatment of ventilated participants with presumed gram-positive hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP), collectively referred to as ventilated nosocomial pneumonia (VNP). Participants with concurrent gram-positive bacteremia are to receive 14 days of active therapy in either treatment arm.

The primary objective is to determine the noninferiority (NI) in all-cause mortality (ACM) within 28 days after randomization of IV tedizolid phosphate compared with IV linezolid in the Intent to Treat (ITT) Analysis Set (NI is declared when the lower bound of the 95% CI > -10).

02

Conditions studied

  • Pneumonia

Browse trials for

03

In context

Pneumonia

1,568 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

This study's enrollment of 726 is above the median of 128 across 977 interventional studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 65 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Requires IV antibiotic therapy with diagnosis of ventilated nosocomial pneumonia
  • Gram-positive bacteria on respiratory Gram stain

Exclusion criteria

Exclusion Criteria:

  • Pneumonia of community, viral, fungal or parasitic etiology
  • Structural lung abnormalities
  • Previous antibiotics for > 24 hours
  • Expected survival of \< 72 hours
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
726 participants (actual)

Study arms

  • Experimental
    Tedizolid phosphate IV

    Ventilated HABP/VABP participants receive tedizolid phosphate 200 mg IV once daily for 7 days, or for 14 days for concurrent bacteremia.

    Drug: Tedizolid phosphate

  • Active comparator
    Linezolid IV

    Ventilated HABP/VABP participants receive linezolid 600 mg IV every 12 hours for 10 days, or for 14 days for concurrent bacteremia.

    Drug: Linezolid

Interventions

  • Tedizolid phosphate IV 200 mg once daily

    Also known as: SIVEXTRO®, TR-701 FA, MK-1986

  • Linezolid IV 600 mg twice daily

    Also known as: ZYVOX®

06

What researchers measure

Primary outcomes

  1. Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population

    The numbers of participants with all-cause mortality within 28 days after randomization was determined in the ITT population. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.

    Time frame: Up to 28 days

Secondary outcomes

  1. Number of Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population

    The numbers of participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.

    Time frame: Up to 28 days

  2. Clinical Response at Test of Cure (TOC) Visit in the Intent-to-Treat (ITT) Population

    The clinical response in the ITT population at the TOC visit (derived from the Investigator's assessment at the EOT and TOC visits) was determined by the investigator to be either: clinical success, clinical failure, or indeterminate. Clinical success was declared when most or all clinical signs were completely resolved, with no new signs of infection, no additional antibiotic therapy was required, and the participant was alive. Indeterminate was declared when the investigator could not determine success or failure. Clinical failure was declared with progression, relapse, or recurrence of new symptoms of infection, or a persistence or insufficient improvement in signs and symptoms of VNP.

    Time frame: 7-14 days after end of therapy - TOC

  3. Clinical Response at Test of Cure (TOC) Visit in the Clinically-Evaluable (CE) Population

    The clinical response in the CE population at the TOC visit (derived from the Investigator's assessment at the EOT and TOC visits) was determined by the investigator to be either: clinical success, clinical failure, or indeterminate. Clinical success was declared when most or all clinical signs were completely resolved, with no new signs of infection, no additional antibiotic therapy was required, and the participant was alive. Indeterminate was declared when the investigator could not determine success or failure. Clinical failure was declared with progression, relapse, or recurrence of new symptoms of infection, or a persistence or insufficient improvement in signs and symptoms of VNP.

    Time frame: 7-14 days after end of therapy - TOC

  4. Number of Methicillin-Susceptible Staphylococcus Aureus (MSSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population

    The number of MSSA-infected participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Participants who had confirmed MSSA culture results from respiratory tract or pleural fluid specimens obtained within 36 hours of study Day 1 were included. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.

    Time frame: Up to 28 days

  5. Number of Methicillin-Resistant Staphylococcus Aureus (MRSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population

    The number of MRSA-infected participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Participants who had confirmed MRSA culture results from respiratory tract or pleural fluid specimens obtained within 72 hours of study Day 1 were included. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.

    Time frame: Up to 28 days

  6. Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiological Intent-to-Treat (mITT) Population

    The number of patients in the mITT population with a favorable response at EOT was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).

    Time frame: 1-3 days after completing study therapy (Days 8-10 or Days 15-17)

  7. Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiologically-Evaluable 1 (ME-1) Population

    The number of patients in the ME-1 population with a favorable response at EOT was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).

    Time frame: 1-3 days after completing study therapy (Days 8-10 or Days 15-17)

  8. Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (mITT) Population

    The number of patients in the mITT population with a favorable response at TOC was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).

    Time frame: 7-14 days after end of therapy - TOC

  9. Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiologically-Evaluable 2 (ME-2) Population

    The number of patients in the ME-2 population with a favorable response at TOC was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).

    Time frame: 7-14 days after end of therapy - TOC

  10. Number of Participants With ≥1 Adverse Events (AEs)

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Safety analysis is based on actual treatment received instead of randomization.

    Time frame: Up to 32 days

  11. Number of Participants Discontinuing Study Therapy Due to an Adverse Event (AE)

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Safety analysis was based on actual treatment received and not randomization.

    Time frame: Up to 14 days

07

Results

Posted Jun 27, 2019

Participant flow

Ventilated participants with presumed gram-positive hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) were enrolled at study sites located in 34 countries.

Participant flow — Overall Study
MilestoneTedizolidLinezolid
Started366360
Treated361357
Completed258254
Not completed108106
Withdrew: Did not receive study drug22
Withdrew: Withdrawal by subject13
Withdrew: At request of sponsor or investigator01
Withdrew: Death10499
Withdrew: Transferred to other care facility11

Outcome measures

PrimaryNumber of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population

The numbers of participants with all-cause mortality within 28 days after randomization was determined in the ITT population. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population
ParticipantsTedizolidLinezolid
Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population10395
Statistical analysis
  • Tedizolid vs Linezolid · Difference in all-cause mortality: -1.8 · 95% CI -8.2 to 4.7Difference and 95% CI were calculated with the Miettinen and Nurminen method without stratification.
SecondaryNumber of Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population

The numbers of participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population
ParticipantsTedizolidLinezolid
Number of Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population4649
Statistical analysis
  • Tedizolid vs Linezolid · Difference in all-cause mortality: -1.6 · 95% CI -10.3 to 7.1Difference and 95% CI were calculated with the Miettinen and Nurminen method without stratification.
SecondaryClinical Response at Test of Cure (TOC) Visit in the Intent-to-Treat (ITT) Population

The clinical response in the ITT population at the TOC visit (derived from the Investigator's assessment at the EOT and TOC visits) was determined by the investigator to be either: clinical success, clinical failure, or indeterminate. Clinical success was declared when most or all clinical signs were completely resolved, with no new signs of infection, no additional antibiotic therapy was required, and the participant was alive. Indeterminate was declared when the investigator could not determine success or failure. Clinical failure was declared with progression, relapse, or recurrence of new symptoms of infection, or a persistence or insufficient improvement in signs and symptoms of VNP.

Time frame:
7-14 days after end of therapy - TOC
Reported as:
Count of participants · Participants
Clinical Response at Test of Cure (TOC) Visit in the Intent-to-Treat (ITT) Population
ParticipantsTedizolidLinezolid
Clinical Success206230
Clinical Failure144110
Indeterminate1620
Statistical analysis
  • Tedizolid vs Linezolid · Difference in clinical success: -7.6 · 95% CI -14.7 to -0.5Difference and 95% CI were calculated with the Miettinen and Nurminen method without stratification.
SecondaryClinical Response at Test of Cure (TOC) Visit in the Clinically-Evaluable (CE) Population

The clinical response in the CE population at the TOC visit (derived from the Investigator's assessment at the EOT and TOC visits) was determined by the investigator to be either: clinical success, clinical failure, or indeterminate. Clinical success was declared when most or all clinical signs were completely resolved, with no new signs of infection, no additional antibiotic therapy was required, and the participant was alive. Indeterminate was declared when the investigator could not determine success or failure. Clinical failure was declared with progression, relapse, or recurrence of new symptoms of infection, or a persistence or insufficient improvement in signs and symptoms of VNP.

Time frame:
7-14 days after end of therapy - TOC
Reported as:
Count of participants · Participants
Clinical Response at Test of Cure (TOC) Visit in the Clinically-Evaluable (CE) Population
ParticipantsTedizolidLinezolid
Clinical Success143146
Clinical Failure12497
Indeterminate00
Statistical analysis
  • Tedizolid vs Linezolid · Difference in clinical success: -6.5 · 95% CI -15.1 to 2.1Difference and 95% CI were calculated with the Miettinen and Nurminen method without stratification.
SecondaryNumber of Methicillin-Susceptible Staphylococcus Aureus (MSSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population

The number of MSSA-infected participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Participants who had confirmed MSSA culture results from respiratory tract or pleural fluid specimens obtained within 36 hours of study Day 1 were included. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Methicillin-Susceptible Staphylococcus Aureus (MSSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population
ParticipantsTedizolidLinezolid
Number of Methicillin-Susceptible Staphylococcus Aureus (MSSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population3132
Statistical analysis
  • Tedizolid vs Linezolid · Difference in all-cause mortality: -1.5 · 95% CI -12.5 to 9.5Difference and 95% CI were calculated with the Miettinen and Nurminen method without stratification.
SecondaryNumber of Methicillin-Resistant Staphylococcus Aureus (MRSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population

The number of MRSA-infected participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Participants who had confirmed MRSA culture results from respiratory tract or pleural fluid specimens obtained within 72 hours of study Day 1 were included. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Methicillin-Resistant Staphylococcus Aureus (MRSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population
ParticipantsTedizolidLinezolid
Number of Methicillin-Resistant Staphylococcus Aureus (MRSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population1420
Statistical analysis
  • Tedizolid vs Linezolid · Difference in all-cause mortality: 3.1 · 95% CI -12.8 to 18.9Difference and 95% CI were calculated with the Miettinen and Nurminen method without stratification.
SecondaryNumber of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiological Intent-to-Treat (mITT) Population

The number of patients in the mITT population with a favorable response at EOT was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).

Time frame:
1-3 days after completing study therapy (Days 8-10 or Days 15-17)
Reported as:
Count of participants · Participants
Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiological Intent-to-Treat (mITT) Population
ParticipantsTedizolidLinezolid
Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiological Intent-to-Treat (mITT) Population123166
Statistical analysis
  • Tedizolid vs Linezolid · Difference in clinical success: -13.1 · 95% CI -21.7 to -4.5Difference and 95% CI were calculated with the Miettinen and Nurminen method without stratification.
SecondaryNumber of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiologically-Evaluable 1 (ME-1) Population

The number of patients in the ME-1 population with a favorable response at EOT was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).

Time frame:
1-3 days after completing study therapy (Days 8-10 or Days 15-17)
Reported as:
Count of participants · Participants
Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiologically-Evaluable 1 (ME-1) Population
ParticipantsTedizolidLinezolid
Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiologically-Evaluable 1 (ME-1) Population123166
Statistical analysis
  • Tedizolid vs Linezolid · Difference in clinical success: -13.1 · 95% CI -21.7 to -4.5Difference and 95% CI were calculated with the Miettinen and Nurminen method without stratification.
SecondaryNumber of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (mITT) Population

The number of patients in the mITT population with a favorable response at TOC was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).

Time frame:
7-14 days after end of therapy - TOC
Reported as:
Count of participants · Participants
Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (mITT) Population
ParticipantsTedizolidLinezolid
Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (mITT) Population117158
Statistical analysis
  • Tedizolid vs Linezolid · Difference in clinical success: -12.5 · 95% CI -21.5 to -3.5Difference and 95% CI were calculated with the Miettinen and Nurminen method without stratification.
SecondaryNumber of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiologically-Evaluable 2 (ME-2) Population

The number of patients in the ME-2 population with a favorable response at TOC was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).

Time frame:
7-14 days after end of therapy - TOC
Reported as:
Count of participants · Participants
Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiologically-Evaluable 2 (ME-2) Population
ParticipantsTedizolidLinezolid
Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiologically-Evaluable 2 (ME-2) Population6574
Statistical analysis
  • Tedizolid vs Linezolid · Difference in clinical success: -13.7 · 95% CI -26.2 to -1.2Difference and 95% CI were calculated with the Miettinen and Nurminen method without stratification.
SecondaryNumber of Participants With ≥1 Adverse Events (AEs)

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Safety analysis is based on actual treatment received instead of randomization.

Time frame:
Up to 32 days
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Adverse Events (AEs)
ParticipantsTedizolidLinezolid
Number of Participants With ≥1 Adverse Events (AEs)327325
SecondaryNumber of Participants Discontinuing Study Therapy Due to an Adverse Event (AE)

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Safety analysis was based on actual treatment received and not randomization.

Time frame:
Up to 14 days
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Therapy Due to an Adverse Event (AE)
ParticipantsTedizolidLinezolid
Number of Participants Discontinuing Study Therapy Due to an Adverse Event (AE)43

Adverse events

Collected over Up to 32 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tedizolid101/357 (28.3%)129/357 (36.1%)176/357 (49.3%)
Linezolid103/361 (28.5%)149/361 (41.3%)175/361 (48.5%)
Most frequent serious events
Showing 10 of 141
Most frequent serious events
EventTedizolidLinezolid
Cardiac arrestCardiac disorders21/35716/361
Septic shockInfections and infestations16/35718/361
Brain oedemaNervous system disorders13/3577/361
Multiple organ dysfunction syndromeGeneral disorders8/35712/361
Cardio-respiratory arrestCardiac disorders7/3576/361
Acute kidney injuryRenal and urinary disorders5/3577/361
SepsisInfections and infestations6/3575/361
PneumoniaInfections and infestations4/3576/361
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/3576/361
ThrombocytopeniaBlood and lymphatic system disorders0/3575/361
Most frequent other events
Most frequent other events
EventTedizolidLinezolid
AnaemiaBlood and lymphatic system disorders56/35751/361
DiarrhoeaGastrointestinal disorders34/35749/361
HypokalaemiaMetabolism and nutrition disorders38/35734/361
ConstipationGastrointestinal disorders31/35728/361
HypotensionVascular disorders27/35725/361
Urinary tract infectionInfections and infestations26/35720/361
Decubitus ulcerSkin and subcutaneous tissue disorders22/35726/361
VomitingGastrointestinal disorders19/35715/361
HypertensionVascular disorders19/35714/361

Baseline characteristics

Age, Continuous
Age, Continuous(Years)TedizolidLinezolidTotal
Mean58.1 ± 18.4158.7 ± 17.4458.4 ± 17.93
Sex: Female, Male
Sex: Female, Male(Participants)TedizolidLinezolidTotal
Female117106223
Male249254503
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TedizolidLinezolidTotal
Hispanic or Latino6561126
Not Hispanic or Latino290289579
Unknown or Not Reported111021
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TedizolidLinezolidTotal
American Indian or Alaska Native112
Asian6870138
Native Hawaiian or Other Pacific Islander000
Black or African American31114
White269258527
More than one race213
Unknown or Not Reported231942
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Alp E, Voss A. Ventilator associated pneumonia and infection control. Ann Clin Microbiol Antimicrob. 2006 Apr 6;5:7. doi: 10.1186/1476-0711-5-7. PubMed 16600048 ↗
  • American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416. doi: 10.1164/rccm.200405-644ST. No abstract available. PubMed 15699079 ↗
  • Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003 Nov 19;290(19):2588-98. doi: 10.1001/jama.290.19.2588. PubMed 14625336 ↗
  • Lan KK, Wittes J. The B-value: a tool for monitoring data. Biometrics. 1988 Jun;44(2):579-85. PubMed 3390511 ↗
  • Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006 Jun 1;42(11):1578-83. doi: 10.1086/503839. Epub 2006 Apr 27. PubMed 16652315 ↗
  • Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother. 2009 Nov;64(5):1035-43. doi: 10.1093/jac/dkp267. Epub 2009 Sep 16. PubMed 19759040 ↗
  • Torres A, Ewig S, Lode H, Carlet J; European HAP working group. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med. 2009 Jan;35(1):9-29. doi: 10.1007/s00134-008-1336-9. Epub 2008 Nov 7. PubMed 18989656 ↗
  • Drusano GL, Liu W, Kulawy R, Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother. 2011 Nov;55(11):5300-5. doi: 10.1128/AAC.00502-11. Epub 2011 Sep 12. PubMed 21911576 ↗
  • Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94. doi: 10.1128/AAC.01733-10. Epub 2011 May 9. PubMed 21555763 ↗
  • Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011 Feb 1;52(3):285-92. doi: 10.1093/cid/cir034. PubMed 21217178 ↗
  • Pletz MW, Burkhardt O, Welte T. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy. Eur J Med Res. 2010 Nov 30;15(12):507-13. doi: 10.1186/2047-783x-15-12-507. PubMed 21163725 ↗
  • Tessier PR, Keel RA, Hagihara M, Crandon JL, Nicolau DP. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother. 2012 May;56(5):2342-6. doi: 10.1128/AAC.06427-11. Epub 2012 Feb 21. PubMed 22354302 ↗
  • Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012 Mar 1;54(5):621-9. doi: 10.1093/cid/cir895. Epub 2012 Jan 12. PubMed 22247123 ↗
  • Mikamo H, Nagashima M, Kusachi S, Fujimi S, Oshima N, De Anda C, Takase A. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid. J Infect Chemother. 2022 Sep;28(9):1235-1241. doi: 10.1016/j.jiac.2022.04.027. Epub 2022 Jun 16. PubMed 35718656 ↗
  • Wunderink RG, Roquilly A, Croce M, Rodriguez Gonzalez D, Fujimi S, Butterton JR, Broyde N, Popejoy MW, Kim JY, De Anda C. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. Clin Infect Dis. 2021 Aug 2;73(3):e710-e718. doi: 10.1093/cid/ciab032. PubMed 33720350 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Jun 2018, 53 months.

Results were first posted in Jun 2019, 1 year after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Pneumonia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 32. This study's 53 months is above that.

Counting every sponsor, half of 67 studies reached it within 17 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2013
First posted
Dec 24, 2013
StartActual
Jan 6, 2014
Primary completionActual
Jun 22, 2018
CompletionActual
Jun 22, 2018
Results first posted
Jun 27, 2019
Last update
Jun 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02019420
Responsible party
Sponsor
First posted
Dec 24, 2013
Start date
Jan 6, 2014
Primary completion
Jun 22, 2018
Completion
Jun 22, 2018
Results posted
Jun 27, 2019
Last update
Jun 27, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion